Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report)’s stock price traded down 1.3% during trading on Monday . The stock traded as low as $3.00 and last traded at $3.00. 16,535 shares were traded during trading, a decline of 60% from the average session volume of 41,094 shares. The stock had previously closed at $3.04.
Medexus Pharmaceuticals Stock Performance
The stock’s fifty day moving average is $2.16 and its two-hundred day moving average is $1.92.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
- Five stocks we like better than Medexus Pharmaceuticals
- How to Use the MarketBeat Stock Screener
- Netflix Adds 19 Million Subscribers, Growth Is Far For Over
- How to Evaluate a Stock Before BuyingÂ
- Tempus AI: A Game-Changer in AI-Powered Healthcare
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Pelosi Bets Big on AI: This Is What You Need to Know
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
